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Abstract
Background: Patients with metastatic colorectal cancer whose disease has progressed on oxaliplatin- and
irinotecan-containing regimens may benefit from EGFR-inhibiting monoclonal antibodies if they do not contain
mutations in the KRAS gene (are “wild type”). It is unknown whether these antibodies, such as cetuximab, are more
efficacious in refractory metastatic colorectal cancer as monotherapy, or in combination with irinotecan. Lack
of mutation in KRAS, BRAF and PIK3CA predicts response to EFGR-inhibitors. The ICECREAM trial examines the
question of monotherapy versus combination with chemotherapy in two groups of patients: those with a
“quadruple wild type” tumour genotype (no mutations in KRAS, NRAS, PI3KCA or BRAF genes) and those with
the specific KRAS mutation in codon G13D, for whom possibly EGFR-inhibitor efficacy may be equivalent.
Methods and design: ICECREAM is a randomised, phase II, open-label, controlled trial comparing the efficacy
of cetuximab alone or with irinotecan in patients with “quadruple wild type” or G13D-mutated metastatic
colorectal cancer, whose disease has progressed on, or who are intolerant of oxaliplatin- and fluoropyrimidine-based
chemotherapy. The primary endpoint is the 6-month progression-free survival benefit of the treatment regimen.
Secondary endpoints are response rate, overall survival, and quality of life. The tertiary endpoint is prediction of
outcome with further biological markers. International collaboration has facilitated recruitment in this prospective
trial of treatment in these infrequently found molecular subsets of colorectal cancer.
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Discussion: This unique trial will yield prospective information on the efficacy of cetuximab and whether this is
further enhanced with chemotherapy in two distinct populations of patients with metastatic colorectal cancer:
the “quadruple wild type”, which may ‘superselect’ for tumours sensitive to EGFR-inhibition, and the rare KRAS
G13D mutated tumours, which are also postulated to be sensitive to the drug. The focus on establishing both
positive and negative predictive factors for the response to targeted therapy is an attempt to improve outcomes,
reduce toxicity and contain treatment costs. Tissue and blood will yield a resource for molecular studies. Recruitment,
particularly of patients with the rare G13D mutation, will demonstrate the ability for international collaboration to run
prospective trials in small colorectal cancer molecular subgroups.
Trial registration: Australian and New Zealand Clinical Trials Registry: ACTRN12612000901808, registered 16
August 2012.
Keywords: Colorectal tumours, Cetuximab, Irinotecan, Clinical trial, Tumour mutations
Background
The ICECREAM study (Irinotecan Cetuximab Evaluation
and the Cetuximab Response Evaluation Among Patients
with G13D Mutation) aims to provide prospective data on
the optimal use of targeted therapies in patients with
metastatic colorectal cancer (mCRC) whose tumours have
progressed on standard chemotherapy. The trial will study
two preselected patient populations in parallel, to deter-
mine whether cetuximab is optimally used as monother-
apy, or in combination with an irinotecan-based regimen.
In retrospective studies, the “quadruple wild type (WT) ”
genotype (no mutations in KRAS, NRAS, PI3KCA or
BRAF genes) appears to select responders to EFGR-
inhibitors (EGFR-I) over and above that of KRAS exon 2
WT alone, which was until recently the extent of standard
mutation testing. Similarly, retrospective data suggest that
patients whose tumours harbour the specific KRAS G13D
mutation may be sensitive to EGFR-I, in contrast to all
other KRAS mutations. To date, no prospective trials of
EGFR-I selected by tumour mutation/WT status have
been undertaken.
Trial results may affect the standard of treatment for
both groups of patients, in particular defining both a
highly sensitive group and potentially providing the
foundation for access to EGFR-I treatment for patients
with KRAS G13D mutated mCRC. The trial was devised
and instigated as an investigator initiated study in
Australia, with participation of leading cancer institutes
in Italy, Spain, Belgium and England.
Rationale for evaluating the addition of irinotecan to
cetuximab in WT patients
The BOND study, undertaken in patients with
irinotecan-refractory mCRC demonstrated a modest
progression-free survival (PFS) benefit for cetuximab
in combination with irinotecan compared with cetuxi-
mab alone [1]. Whilst the benefits were modest, tox-
icity was increased with the combination. Also, due
to being conducted in an era prior to RAS testing, as
well as the lack of tissue availability, RAS testing has not
been retrospectively performed on the BOND cohort.
Therefore it remains unclear whether the addition of irino-
tecan will provide additive benefit in patients selected for
KRAS WT tumours. The landmark EGFR-I phase III trials
in refractory mCRC elected to use the EGFR monoclonal
antibodies (cetuximab and panitumumab) as monotherapy
[2–4]; however, clinical use in Australia and worldwide is
divided equally between monotherapy and doublet therapy
in the refractory setting. Therefore, the use of cetuximab
alone versus combination with irinotecan remains an im-
portant, unanswered question.
Rationale for studying “quadruple wild type” tumours
EGFR-I administration is now restricted to patients with
RAS WT tumours, following retrospective analyses that
initially demonstrated lack of mutation in KRAS exon 2
(codons 12 and 13) as a positive predictive marker [4, 5],
with subsequent extension of predictive molecular
markers to include other exons of KRAS as well as of
NRAS (exons 2, 3, 4) [6–8]. Less certain, but suggestive
are data showing that sensitivity to EGFR-I also depends
on the WT status of BRAF (exon 15) and PIK3CA (exon
20) genes [9, 10].
Rationale for studying EGFR-I in patients with G13D
mutations
Multiple retrospective analyses, initially in refractory
mCRC [11], then in 1st and 2nd line chemotherapy-
EGFR-I combinations [12], suggested that the subgroup
with the specific codon 13 mutation: G13D appear to
derive benefit from cetuximab therapy to a similar ex-
tent as KRAS WT patients. This is also supported in a
meta-analysis [13]. The KRAS exon 2 mutation c.38G >
A: pGly13Asp (G13D) accounts for ~19 % of KRAS mu-
tations, with an absolute incidence of 8 % in mCRC [11].
Preclinical studies in cell lines and xenograft models
have demonstrated a response to cetuximab and block-
ade of the EGFR kinase pathway in the G13D mutants,
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but not in other (eg G12V) mutants [11]. Based on this
data, the use of cetuximab for these patients harbouring
the rare G13D KRAS mutation is becoming an increas-
ingly relevant clinical predicament.
Results from the treatment of patients with G13D
mutations varied in a pooled analysis of trials with pani-
tumumab (a fully humanized EGFR-I) covering all lines
of treatment of mCRC [14]. In one first line study, pa-
tients with a G13D mutation treated with panitumumab
had an unfavourable overall survival, whereas patients
with a G12V mutation had a favourable outcome, which
was the opposite finding to cetuximab studies [6]. How-
ever, analysis of outcomes of patients with G13D tu-
mours showed a trend to benefit from panitumumab
when compared with placebo [14]. These data further
support the need for prospective studies in patients with
G13D tumour mutations.
The enriched group of patients being examined in the
ICECREAM trial will yield valuable information regard-
ing other features associated with response to EGFR-I,
in particular the depth of response to treatment, which
has been shown to be a predictor of clinical benefit and
survival [15–17]. Biological substudies examining add-
itional biomarkers in both subgroups are planned.
Methods and design
Study design and objectives
ICECREAM is a randomised, open-label, phase II
study of cetuximab monotherapy versus the combin-
ation of cetuximab and irinotecan. The primary object-
ive is to determine the 6-month progression free
survival (PFS) benefit of cetuximab alone or in com-
bination with irinotecan in patients with KRAS, NRAS,
BRAF and PIK3CKA wild type mCRC or KRAS G13D
mutated mCRC. PFS is defined as the time from random-
isation to disease progression according to RECIST
criteria, version 1.1 [18]. Secondary objectives are to deter-
mine the response rate (as complete or partial responses
according to RECIST criteria, version 1.1) in patients with
“quadruple wild type” or KRAS G13D mutated mCRC.
Overall survival benefit in the two patient cohorts will be
determined based on death from any cause. The study will
evaluate quality of life with FACT-C (Functional As-
sessment of Cancer Therapy), DLQI (Dermatology
Quality of Life Index Questionnaire), and FACT-EGFRI 18
(Functional Assessment of Cancer Therapy, pertaining spe-
cifically to Epidermal Growth Factor Receptor Inhibition).
Tertiary and correlative objectives are to undertake
exploratory studies of biological markers as predictors of
outcome. Early tumour response will be measured by
assessment of tumour shrinkage on CT imaging performed
at 6 weeks post first treatment, based on independent re-
view of volumetric tumour size.
Biological substudies aim to improve understanding of
the mechanisms of cetuximab and any interaction with iri-
notecan in wild type and G13D mutated tumours. Since
the identification of new biomarkers correlating with dis-
ease activity, and the efficacy and safety of treatments are
rapidly evolving, a definitive list of biomarker studies
remains to be determined at the time of these studies.
Trial organisation
The trial was developed by Australian clinicians in
collaboration with key international clinicians. The
Australasian Gastrointestinal Trials Group (AGITG) is
the study sponsor and the trial is coordinated by the
NHMRC Clinical Trials Centre (CTC) at the University
of Sydney, Australia. The legal sponsor in the European
Union (EU) is Hammersmith Hospital. Randomisation
and data collection are performed electronically and the
CTC is responsible for management of safety, ethical
and regulatory reporting, central coordination of study
sites and management of statistical analyses. The trial is
registered on the Australian and New Zealand Clinical
Trials Registry (ACTRN12612000901808).
Statistical methods
The sample size of 100 patients is comprised of 50 pa-
tients with confirmed “quadruple wild type” status and
50 patients with a confirmed G13D tumour mutation.
An intention to treat analysis will be undertaken, with
the inclusion of all randomised patients.
In keeping with the randomized phase II study design,
PFS was selected as the appropriate primary endpoint as
this would not be influenced by subsequent cross over
from monotherapy to combination treatment, which
may occur at progression on study. Statistical assump-
tions were on the basis of retrospective data (Table 1)
with a median PFS of 1.8 months in the cetuximab-
alone arm versus 4.0 months for patients with KRAS
G13D–mutated tumors receiving any cetuximab therapy
[11]. This corresponds to a 6-month PFS rate of ap-
proximately 10 % for the monotherapy group and 35 %
for the combination group. The G13D component of the
study planned to recruit 25 patients per arm to match
the wild-type cohort. This enabled 80 % power (α = .05)
to detect an improvement from 15 to 40 % in 6-month
PFS by using the Simon design for phase II trials. This
magnitude of effect was chosen because we were inter-
ested in detecting a similar degree of benefit in the
KRAS G13D–mutation population that was anticipated
to be practice changing in patients with wild-type tu-
mors. PFS and OS treatment effects were described by
using hazard ratios (HRs) that were estimated by using
Cox proportional hazards models. Completeness of the
PFS was estimated by using a published equation [19].
Waterfall plots were constructed by using the biggest
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decrease compared with baseline in the sum of the
target lesions. Patients with a decreased sum of target le-
sions but with new non-target lesions were set to a zero
change but still qualified as having progressive disease.
QoL changes over time were modeled by using general-
ized estimating equations. Analyses used SAS v9.3 (SAS
Institute, Cary, NC).
Planned futility analysis
As the activity of the combination is of particular interest
in patients with G13D KRAS mutated tumours, Simon’s II
stage design was applied to this group of patients. Futility
will be declared if in the first seven eligible patients having
at least six months of combination treatment, all seven
patients have progressed.
Pre-trial screening procedures and randomisation and
stratification
Entry into the study is conditional on confirmation of
tumour genotype by means of mutation analysis of rep-
resentative samples of diagnostic tumour tissue. KRAS
G13D status is determined by local pathology laborator-
ies, whereas “quadruple wild type” status is determined
by a central reference laboratory, the Centre for Transla-
tional Pathology, Melbourne, Australia. Archival tumour
samples from the primary colorectal cancer or any meta-
static site are acceptable for mutation analysis. All speci-
mens are received as formalin fixed, paraffin embedded
tissue biopsy blocks (FFPE), which upon arrival are cut
into 10 μm sections by microtome and transferred onto
glass slides before de-waxing and DNA extraction. An
additional 4 μm slide section is stained with haematoxy-
lin and eosin, examined by a pathologist to determine
and mark the region of tumour, and then used to deter-
mine the areas of tumour to be macrodissected from
unstained slides. DNA is extracted using Qiagen FFPE
DNA extraction kits and successful DNA extraction is
confirmed by Qubit DNA quantitation and LabChipGX
DNA fragmentation assessment. For Sanger sequencing,
targeted regions of interest from exon 15 of the BRAF
gene, exons 9 and 20 of the PIK3CA gene, and exons 2,
3, and 4 of both KRAS and NRAS genes are amplified
separately by PCR and sequenced using BigDye termin-
ator chemistry on an ABI 3730 genetic analyser.
Mutation analysis uses Mutation Surveyor software. For
next generation sequencing (NGS) analysis, targeted re-
gions of interest from exon 15 of the BRAF gene, exons
9 and 20 of the PIK3CA gene, and exons 2, 3, and 4 of
both KRAS and NRAS genes are amplified and linked to
barcoded NGS adapters with a two-step multiplex PCR
protocol. The resulting library is sequenced on an Illu-
mina MiSeq next generation sequencer. Mutations are
detected with MiSeq Reporter software.
Written informed consent must be obtained, and pa-
tients must be randomised before starting the study
treatment and planned to start within 14 days of
randomisation.
Patients are centrally randomised in a 1:1 ratio and
be stratified according to “quadruple wild type” or
KRAS G13D mutational status, and treating hospital.
This publication represents the current protocol ver-
sion (V4).
The ICECREAM trial opened in November 2012 with
a recruitment period of two years.
Inclusion criteria
1. Males or females with histologically confirmed
colorectal cancer, aged 18 years or older
2. Metastatic disease not amenable to complete resection,
as determined by investigator
3. Measurable or evaluable disease, as assessed by a CT
(computed tomography) scan of the chest, abdomen
and pelvis according to RECIST v1.1 criteria, within
21 days prior to randomisation
4. Prior confirmation of tumour “quadruple wild type”
status – ie.no mutations in KRAS and NRAS (exons
2, 3, 4), BRAF exon 15, and PIK3CA exons 9 and 20
or KRAS G13D mutant, by means of mutation or
relevant analysis performed on representative samples
of diagnostic tumour tissue
5. ECOG (Eastern Cooperative Oncology Group)
performance status 0-1
6. Received and progressed on, or intolerant of all
therapies listed below, where failure is defined as
radiological progression during therapy, toxicity
limiting further therapy or progression within
6 months of prior treatment. Previous treatment
Table 1 Summary of current clinical trial PFS data on which statistical calculations are based
KRAS unknown KRAS WT KRAS mutant KRAS G13D
BOND study [1] cetuximab alone vs
cetuximab + irinotecan
6 m PFS = 8 %
vs. 30 %
NA NA NA
CO.17 [4] cetuximab vs best supportive care N/A 6 m PFS cetuximab = 30 % 6 m PFS < 5 %
De Roock [11] cetuximab vs no cetuximab N/A Median PFS 4.2 m vs 1.9 m Median PFS 1.9 m vs 1.8 m Median PFS 4.0 m vs 1.7 m
Tepjar [12] cetuximab vs no cetuximab as
1st line treatment
Not relevant Median PFS 9.6 m vs 7.6 m Median PFS 6.7 m vs 8.1 m Median PFS 7.4 m vs 6.0 m
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should have ceased at least 14 days prior to
randomisation.
– thymidylate synthase inhibitor (e.g. 5-fluorouracil,
capecitabine, raltitrexed, tegafur − uracil, S1).
Thymidylate synthase inhibitors may have been
given as monotherapy or in combination with
oxaliplatin or irinotecan
– irinotecan-containing regimen (ie. single agent or
in combination) and still able to tolerate
additional irinotecan treatment)
– oxaliplatin-containing regimen OR have
documented unsuitability for an oxaliplatin-
containing regimen
7. Adequate haematological and renal function within
14 days prior to randomization
– Platelets ≥ 75 × 109/L, Haemoglobin ≥ 80 g/L,
ANC (absolute neutrophil count) ≥ 1.0 × 109/L
– Serum creatinine ≤ 1.5 × institutional ULN or
creatinine clearance >50 ml/min
8. Adequate liver function with total serum bilirubin
≤2.5 x ULN, and both ALT (alanine transaminase)
and AST (aspartate transaminase) ≤5.0 x ULN
within 14 days prior to randomization. Patients
with Gilbert’s syndrome may be included as long
as unconjugated bilirubin levels fall within these
limits
9. Life expectancy at least 12 weeks
10. Study treatment both planned and able to start
within 14 days of randomisation
11. Willing and able to comply with all study
requirements, including treatment, timing
and/or nature of required assessments
12. Signed, written informed consent.
Exclusion criteria
1. Prior treatment with cetuximab or other drugs
targeting the EGFR pathway, such as panitumumab,
gefitinib, erlotinib
2. Severe restrictive lung disease or radiological
pulmonary findings of interstitial lung disease on
the baseline chest CT which, in the opinion of
the investigator, represents significant pathology
3. Brain metastases that are either untreated,
symptomatic, or which have not been stable
for at least one month following treatment
4. History of other malignancies except where treated
with curative intent AND with no current evidence
of disease AND considered not to be at risk of
future recurrence
5. Severe or uncontrolled cardiovascular disease
(e.g. acute coronary syndromes, cardiac failure
NYHA (New York Heart Association) III or IV,
clinically relevant myopathy, history of myocardial
infarction within the last 12 months, significant
arrhythmias)
6. Concurrent illness, including severe infection that
may jeopardize the ability of the patient to undergo
the procedures outlined in this protocol with
reasonable safety
7. Presence of any psychological, familial, sociological
or geographical condition potentially hampering
compliance with the study protocol and follow-up
schedule, including alcohol dependence or drug abuse
8. Pregnancy, lactation, or inadequate contraception.
Women must be postmenopausal, infertile, or use
a reliable means of contraception. Women of
childbearing potential must have a negative
pregnancy test done within 7 days prior to
registration. Men must have been surgically
sterilised or use a (double if required) barrier
method of contraception.
Administration of study treatment
Patient will be randomised to one of two treatment arms:
Arm A
 Cetuximab monotherapy (Cetuximab 400 mg/m2 IVI
on Day 1, followed by 250 mg/m2 IVI every week).
Arm B
 Cetuximab and irinotecan combination therapy
(Cetuximab 400 mg/m2 IVI on Day 1, followed by
250 mg/m2 IVI every week; Irinotecan 180 mg/m2
IVI on Day 1 after cetuximab infusion, then every
14 days).
Body surface area (BSA) will be calculated using actual
body weight. Irinotecan dose is capped at that for BSA
2.2 m2; and no dose capping is stipulated for cetuximab.
The starting dose of irinotecan is at the discretion of
the investigator, taking into account prior irinotecan
dosing and adjustments. Whilst on study, all patients
will be permitted a maximum of two further reductions
in irinotecan (level 1 of −20 % and level 2 of −40 %), ex-
cluding dose reductions at commencement. Cetuximab
dose reductions are permitted beyond level 2 (dose level 3
of 100 mg/m2, and dose level 4 of 50 mg/m2). Treatment
will continue until disease progression, unacceptable tox-
icity, or patient or physician request for cessation.
In Australia, for patients with KRAS WT colorectal
cancer, cetuximab and irinotecan are approved treat-
ments and will be supplied through the Pharmaceutical
Benefits Scheme (PBS) and available through local hos-
pital supply. For Australian patients with KRAS G13D
mutant colorectal cancer, cetuximab will be supplied by
Merck Serono Australia Pty Ltd.
In England, Italy and Spain only patients with the
G13D tumour mutation will be recruited and cetuximab
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is supplied by Merck Serono Australia Pty Ltd. The
Belgian site will recruit patients with “KRAS quad wild
type” tumour status and the study treatments are ap-
proved for use and sourced as per local hospital supply.
Cetuximab administration
Cetuximab therapy should be administered prior to cyto-
toxic chemotherapy by intravenous infusion at an initial
dose of 400 mg/m2 (over target duration of 120 min) and
further weekly infusions at a dose of 250 mg/m2 (over
target duration of 60 min). The infusion rate must not ex-
ceed 10 mg/min. Normal (0.9 %) saline solution is used to
flush the line at the end of the infusion. Close monitoring
of vital signs of the patient must be checked before, during
and at end of the infusion and for at least one hour after
the end of the infusion. The patient must be pre-treated
with an antihistamine (e.g. loratadine) and dexamethasone
prior to every infusion to reduce the risk of a hypersensi-
tivity reaction. Cetuximab must not be mixed with any
other substance.
Irinotecan administration
Irinotecan will be administered by intravenous infusion
over 90 min, protected from light. Close monitoring of
vital signs of the patient must be checked before, during
and at end of the infusion for cholinergic symptoms (ie.
early onset diarrhoea, runny nose, increased salivation,
miosis, lacrimation, diaphoresis or flushing). If these
symptoms develop, the infusion must be stopped, vital
signs recorded and the patient reviewed according to local
institutional guidelines. The patient may be pre-treated
with a 5HT3-antagonist, corticosteroid and atropine.
Dose modifications and concomitant medications
Adverse events will be graded according to National
Cancer Institute Common Terminology Criteria for
Adverse Events (CTCAE) version 4.0. If there is a re-
quirement to delay treatment due to toxicity, and that
toxicity can be attributed to one specific drug, then the
other treatments can be continued on schedule. If irino-
tecan is delayed for ≥28 days, then the patient must
cease irinotecan and should continue cetuximab mono-
therapy. Cetuximab treatment may also be delayed for a
maximum of 28 days.
In general, treatment should be withheld during ad-
verse events of severity grade 3–4, and not restarted
until the adverse event has resolved to grade 0–1, at the
investigator’s discretion if not otherwise indicated in the
protocol. If the adverse event (not including skin tox-
icity) has not resolved to grade 1 after delay of treatment
for 28 days, then study treatment should be discontin-
ued. Treatment should not be delayed or modified for
alopecia of any grade.
Specified dose reductions apply to all subsequent doses
of the study drug. If a patient experiences several adverse
events with differing recommendations, then the modifi-
cation that results in the longest delay and lowest dose
should be used. Dose escalations or dose re-escalations
after reductions for adverse events are prohibited. All pal-
liative and supportive care measures and medications may
be administered at the Investigator’s discretion unless
otherwise stated in the dose modifications.
Treatment discontinuation
Study treatment will be permanently discontinued for
documented progressive disease as per RECIST 1.1; un-
acceptable toxicity (as determined by the patient or
treating clinician); delay of treatment for more than
28 days due to treatment-related adverse events; if the
treating clinician determines that continuation of treat-
ment is not in the patient’s best interest; for occurrence
of an exclusion criterion affecting patient safety, e.g.
pregnancy or psychiatric illness; failure to comply with
the protocol, e.g. repeatedly failing to attend scheduled
assessments, or if the patient withdraws their consent to
participate in the study. Treatment after discontinuation
of study treatment will be at the discretion of the
patient’s clinician.
Ethics, informed consent and safety
The study will be performed in accordance with the
Declaration of Helsinki and with all applicable regulatory
requirements in Australia and in the EU Directive. Insti-
tutional ethics approval is required, and patients will
provide written, informed consent. Central Ethics ap-
proval was obtained by the Clinical Trials Centre (CTC)
from the Sydney Local Health District Ethics Review
Committee, Royal Prince Alfred Hospital Zone, Sydney,
Australia.
Discussion
Identifying biomarkers of sensitivity to anticancer agents
is the key to tailoring individual therapy, to maximise
benefit and reduce toxicity. KRAS status as a marker of
sensitivity to EGFR-I was identified in a retrospective
analysis of the CO.17 study [4], with the near-perfect fit
of KRAS mutants having no benefit from this class of
agents becoming adopted into standard practice without
prospective verification. At the time, mutation testing of
the KRAS gene was limited to exon 2 only. Further ana-
lysis has led to the identification of particular predictive
subgroups which may have differential benefit from
EGFR-I. The first group is patients with tumours har-
bouring the KRAS exon 2 G13D mutation, who in retro-
spective series (with small numbers only) appear to
respond to EGFR-I (in trials before KRAS selection be-
came an eligibility criteria), but are currently precluded
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from accessing such treatment. The second group are
patients who perhaps should be spared from having inef-
fective treatment, as they seem not to respond to EFGR-
I because of mutations in other exons of KRAS (exons 3
and 4) or in the NRAS, BRAF and PI3KCA genes. The
superselection of responsive patients and exclusion of
patients unlikely to benefit from EGFR-I needs prospect-
ive validation.
ICECREAM is an investigator-initiated, randomised,
phase II trial being conducted through the Australian
Gastro-intestinal Trials Group (AGITG) and coordinated
by the Clinical Trials Centre (CTC) at the University of
Sydney. Initially an international phase III study for the
G13D mutated population was proposed, but the numbers
for this subgroup were considered unachievable. Indeed,
both the necessity as well as the challenge of performing
prospective randomised trials in small molecularly defined
subgroups such as this has been well recognised [20]. One
strategy to ensure successful recruitment has been to open
in key international sites within several countries, with
strongly publicised and encouraged cross referral to trial
sites facilitating good uptake.
The issue of whether cetuximab activity in refractory
metastatic colorectal cancer is enhanced by the addition
of irinotecan chemotherapy is the other important ques-
tion addressed by the ICECREAM trial. There is preclin-
ical evidence that irinotecan may enhance the efficacy of
cetuximab in the G13D mutant subgroup [11] and clinical
evidence, from the BOND study [1], in an unselected re-
fractory mCRC population. Examination of the role of
addition of chemotherapy in a highly selected subgroup
such as the “quadruple wild type” is therefore important.
Summary
Therefore, this prospective study addresses the efficacy of
cetuximab monotherapy compared to combination with
irinotecan in two molecularly defined subpopulations of
patients with refractory metastatic colorectal cancer, either
“quadruple wild type” tumours or KRAS G13D mutated
tumours. Results will inform the need for larger phase III
studies, as well as prove that randomised trials in rare mo-
lecular subtypes of CRC can be successfully completed
using international collaborative networks.
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